The decrease in procarboxypeptidase U (TAFI) concentration in acute ischemic stroke correlates with stroke severity, evolution and outcome

摘要: See also Willemse JL, Brouns R, Heylen E, De Deyn PP, Hendriks DF. Carboxypeptidase U (TAFIa) activity is induced in vivo ischemic stroke patients receiving thrombolytic therapy. J Thromb Haemost 2008; 6: 200–2. Summary. Background and objectives: Procarboxypeptidase (proCPU, TAFI) concentration plasma potentially related to thrombotic tendency, elevated proCPU levels have been reported patients. Improved insight into the role of acute essential for development more adequate therapeutics that may include carboxypeptidase inhibitors. In this study we investigated whether kinetic profile are initial severity, evolution subacute phase long-term outcome. Methods: Plasma was assessed 136 at admission (7.5 h after onset), 24 h, 72 h day 7 onset. We evaluated relation between change concentrations (a) severity (patients with TIA vs. patients, NIHSS score admission), (b) (stroke progression, infarct volume 72 h), (c) outcome (mRS month 3). Results: ProCPU decreased significantly first onset thereafter returned baseline. This biphasic time course, its nadir 72 h, pronounced severe stroke, unfavourable poor Conclusions: The decrease correlates evolution,